Patent Application
Utility
PCT National Stage
App. No. 18/257,450
· Confirmation No. 6662
METHODS OF TREATING ACHONDROPLASIA
Inventors:
Riccardo Panicucci, Susan Arangio, Carl Dambkowski, Michael Henderson, Daniela Rogoff, Michael Monteith, Lihua Zhang
Applicant:
QED Therapeutics, Inc.
Final Rejection Mailed
View Publication ↗
|
⬇ PDF
|
Code | Description | Pages | ||
|---|---|---|---|---|---|
| 2026-08-18 | CTFR |
Final Rejection | 30 | View | |
| 2026-08-18 | 892 |
List of references cited by examiner | 1 | View | |
| 2026-08-18 | SRFW |
Search information including classification, databases and other search related notes | 2 | View | |
| 2026-08-18 | SRNT |
Examiner's search strategy and results | 4 | View | |
| 2026-08-18 | 1449 |
List of References cited by applicant and considered by examiner | 2 | View | |
| 2026-08-18 | SRNT |
Examiner's search strategy and results | 7 | View | |
| 2026-07-08 | A... |
Amendment/Request for Reconsideration-After Non-Final Rejection | — | View | |
| 2026-07-08 | FOR |
Foreign Reference | 71 | View | |
| 2026-07-08 | FOR |
Foreign Reference | 12 | View | |
| 2026-07-08 | IDS |
Information Disclosure Statement (IDS) Form (SB08) | 2 | View | |
| 2026-07-08 | TRAN.LET |
Transmittal Letter | 2 | View | |
| 2026-07-08 | IDS.SIZEFEE |
Assertion regarding Information Disclosure Statement (IDS) Size Fee (SB/08C) | 1 | View | |
| 2026-07-08 | A... |
Amendment/Request for Reconsideration-After Non-Final Rejection | 1 | View | |
| 2026-07-08 | CLM |
Claims | 11 | View | |
| 2026-07-08 | REM |
Applicant Arguments/Remarks Made in an Amendment | 9 | View | |
| 2026-07-08 | N417 |
Electronic Filing System Acknowledgment Receipt | 3 | View | |
| 2026-07-08 | N417.PYMT |
Electronic Fee Payment | 2 | View | |
| 2026-04-08 | CTNF |
Non-Final Rejection | 17 | View | |
| 2026-04-08 | 892 |
List of references cited by examiner | 1 | View | |
| 2026-04-08 | SRFW |
Search information including classification, databases and other search related notes | 1 | View | |
| 2026-04-08 | FOR |
Foreign Reference | 15 | View | |
| 2026-04-08 | SRNT |
Examiner's search strategy and results | 4 | View | |
| 2026-04-08 | BIB |
Bibliographic Data Sheet | 2 | View | |
| 2026-04-08 | 1449 |
List of References cited by applicant and considered by examiner | 2 | View | |
| 2026-04-08 | 1449 |
List of References cited by applicant and considered by examiner | 2 | View | |
| 2026-04-08 | SRNT |
Examiner's search strategy and results | 5 | View | |
| 2026-03-10 | 371P |
Documents submitted with 371 (National Stage) Applications | 15 | View | |
| 2026-03-10 | IDS.SIZEFEE |
Assertion regarding Information Disclosure Statement (IDS) Size Fee (SB/08C) | 1 | View | |
| 2026-03-10 | FOR |
Foreign Reference | 55 | View | |
| 2026-03-10 | P.PAMPHLET |
WIPO Publication - Non-English version | 44 | View | |
| 2026-03-10 | IDS |
Information Disclosure Statement (IDS) Form (SB08) | 2 | View | |
| 2026-03-10 | TRAN.LET |
Transmittal Letter | 2 | View | |
| 2026-03-10 | N417 |
Electronic Filing System Acknowledgment Receipt | 3 | View | |
| 2025-12-15 | ELC. |
Response to Election / Restriction Filed | — | View | |
| 2025-12-15 | XT/ |
Extension of Time | 1 | View | |
| 2025-12-15 | N417.PYMT |
Electronic Fee Payment | 2 | View | |
| 2025-12-15 | ELC. |
Response to Election / Restriction Filed | 1 | View | |
| 2025-12-15 | SPEC |
Specification | 1 | View | |
| 2025-12-15 | CLM |
Claims | 14 | View | |
| 2025-12-15 | REM |
Applicant Arguments/Remarks Made in an Amendment | 3 | View | |
| 2025-12-15 | N417 |
Electronic Filing System Acknowledgment Receipt | 3 | View | |
| 2025-12-15 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2025-09-15 | CTRS |
Requirement for Restriction/Election | 7 | View | |
| 2025-09-15 | 892 |
List of references cited by examiner | 1 | View | |
| 2024-03-14 | APP.FILE.REC |
Filing Receipt | 4 | View | |
| 2024-03-14 | M903 |
Notice of Designated Office (DO) / Elected Office (EO) Acceptance Mailed | 2 | View | |
| 2024-03-14 | WCLM |
Claims Worksheet (PTO-2022) | 1 | View | |
| 2024-03-14 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2024-02-02 | PEFR |
Applicant Response to Pre-Exam Formalities Notice | — | View | |
| 2024-02-02 | N417.PYMT |
Electronic Fee Payment | 2 | View | |
| 2024-02-02 | REF.OTHER |
Other reference-Patent/Application/Search Documents | 16 | View | |
| 2024-02-02 | FOR |
Foreign Reference | 33 | View | |
| 2024-02-02 | FOR |
Foreign Reference | 85 | View | |
| 2024-02-02 | FOR |
Foreign Reference | 39 | View | |
| 2024-02-02 | OATH |
Oath or Declaration filed | 7 | View | |
| 2024-02-02 | FOR |
Foreign Reference | 67 | View | |
| 2024-02-02 | XT/ |
Extension of Time | 1 | View | |
| 2024-02-02 | IDS |
Information Disclosure Statement (IDS) Form (SB08) | 2 | View | |
| 2024-02-02 | FOR |
Foreign Reference | 50 | View | |
| 2024-02-02 | FOR |
Foreign Reference | 15 | View | |
| 2024-02-02 | N417 |
Electronic Filing System Acknowledgment Receipt | 5 | View | |
| 2024-02-02 | TRAN.LET |
Transmittal Letter | 2 | View | |
| 2024-02-02 | PEFR |
Applicant Response to Pre-Exam Formalities Notice | 1 | View | |
| 2024-02-02 | CLM |
Claims | 6 | View | |
| 2024-02-02 | REM |
Applicant Arguments/Remarks Made in an Amendment | 1 | View | |
| 2024-01-11 | NTC.PUB |
Notice of Publication | 1 | View | |
| 2023-10-02 | APP.FILE.REC |
Filing Receipt | 4 | View | |
| 2023-10-02 | 371.FEE.M923 |
371 (National Stage) Supplemental Fees Missing - Form M923 | 2 | View | |
| 2023-10-02 | WCLM |
Claims Worksheet (PTO-2022) | 1 | View | |
| 2023-10-02 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2023-10-02 | WELCOME.LET |
Welcome Letter from USPTO Director and Deputy Director | 1 | View | |
| 2023-06-14 | A.PE |
Preliminary Amendment | — | View | |
| 2023-06-14 | N417 |
Electronic Filing System Acknowledgment Receipt | 3 | View | |
| 2023-06-14 | N417.PYMT |
Electronic Fee Payment | 2 | View | |
| 2023-06-14 | A.PE |
Preliminary Amendment | 1 | View | |
| 2023-06-14 | SPEC |
Specification | 1 | View | |
| 2023-06-14 | REM |
Applicant Arguments/Remarks Made in an Amendment | 1 | View | |
| 2023-06-14 | ADS |
Application Data Sheet | 10 | View | |
| 2023-06-14 | 371P |
Documents submitted with 371 (National Stage) Applications | 1 | View | |
| 2023-06-14 | TRNA |
Transmittal of New Application | 3 | View | |
| 2023-06-14 | P.N.101.CONV |
PCT/RO/101 - Request form for new International Application - Conventional | 5 | View | |
| 2023-06-14 | FRPR |
Certified Copy of Foreign Priority Application | 79 | View | |
| 2023-06-14 | ABST |
Abstract | 1 | View | |
| 2023-06-14 | SPEC |
Specification | 54 | View | |
| 2023-06-14 | CLM |
Claims | 8 | View |
Inventors
Riccardo Panicucci
Bluffton, SC
Susan Arangio
Los Altos, CA
Carl Dambkowski
San Mateo, CA
Michael Henderson
San Francisco, CA
Daniela Rogoff
Mountain View, CA
Michael Monteith
Raleigh, NC
Lihua Zhang
Cary, NC
Attorneys & Agents of Record
Classification
USPC
424/465
A61K9/2077
A61K31/506
A61P19/04
A61P43/00
A61K9/0053
A61K9/2009
A61K9/2013
A61K9/2018
A61K9/2027
A61K9/2054
A61K9/2072
Prosecution
- Examiner
- SCOTLAND, REBECCA LYNN
- Art Unit
- 1615
- Customer No.
- 51414
- Docket No.
- QED-007WOUS
- Confirmation No.
- 6662
Publication
- Pub. No.
- US20240009193A1
- Pub. Date
- 2024-01-11
Parent
PCT
is a National Stage Entry of
→
PCT/US2021/064033
Filed 2021-12-17
· Final Rejection Mailed
Parent
Claims priority from a provisional application
→
App. 63/127,576
Filed 2020-12-18
· Provisional Application Expired
Child
is a Division of
→
App. 19/746,464
Filed 2026-07-17
· Application Undergoing Preexam Processing
BRIDGEBIO PHARMA, INC.,
QED THERAPEUTICS, INC.,
EIDOS THERAPEUTICS, INC.,
ML BIO SOLUTIONS INC.,
CALCILYTIX THERAPEUTICS INC.,
ADRENAS THERAPEUTICS INC.,
PHOENIX TISSUE REPAIR, INC.,
NAVIRE PHARMA, INC.,
VENTHERA, INC.,
MOLECULAR SKIN THERAPEUTICS, INC.,
CANTERO THERAPEUTICS, INC.,
COA THERAPEUTICS, INC.,
PORTAL THERAPEUTICS, INC.,
BRIDGEBIO GENE THERAPY RESEARCH, INC.,
FERRO THERAPEUTICS, INC.
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL
Recorded 2025-03-05
from
ADRENAS THERAPEUTICS INC.,
BRIDGEBIO GENE THERAPY RESEARCH, INC.,
BRIDGEBIO PHARMA, INC.,
CALCILYTIX THERAPEUTICS INC.,
CANTERO THERAPEUTICS, INC.,
COA THERAPEUTICS, INC.,
EIDOS THERAPEUTICS, INC.,
FERRO THERAPEUTICS, INC.,
ML BIO SOLUTIONS INC.,
MOLECULAR SKIN THERAPEUTICS, INC.,
NAVIRE PHARMA, INC.,
PHOENIX TISSUE REPAIR, INC.,
PORTAL THERAPEUTICS, INC.,
QED THERAPEUTICS, INC.,
SUB21, INC.,
THERAS, INC.,
VENTHERA, INC.
SECURITY INTEREST
Recorded 2024-01-19
from
ADRENAS THERAPEUTICS INC.,
BRIDGEBIO GENE THERAPY RESEARCH, INC.,
CALCILYTIX THERAPEUTICS INC.,
CANTERO THERAPEUTICS, INC.,
COA THERAPEUTICS, INC.,
FERRO THERAPEUTICS, INC.,
MOLECULAR SKIN THERAPEUTICS, INC.,
NAVIRE PHARMA, INC.,
PHOENIX TISSUE REPAIR, INC.,
PORTAL THERAPEUTICS, INC.,
SUB21, INC.,
VENTHERA, INC.
SECURITY INTEREST
Recorded 2024-01-17
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this application's details
Quick Facts
- App. No.
- 18/257,450
- Filed
- 2023-06-14
- Pub. No.
- US20240009193A1
- Examiner
- SCOTLAND, REBECCA LYNN
- Art Unit
- 1615
External Links